Edition:
United Kingdom

GW Pharmaceuticals PLC (GWPH.OQ)

GWPH.OQ on NASDAQ Stock Exchange Global Market

131.99USD
18 Jan 2018
Change (% chg)

$-0.44 (-0.34%)
Prev Close
$132.43
Open
$132.47
Day's High
$133.50
Day's Low
$130.89
Volume
91,754
Avg. Vol
114,135
52-wk High
$140.27
52-wk Low
$92.77

Chart for

About

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company's lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD). The Company offers... (more)

Overall

Beta: 2.68
Market Cap(Mil.): $2,789.42
Shares Outstanding(Mil.): 2.11
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 85.75 16.58
EPS (TTM): -- -- --
ROI: -- 3.21 10.60
ROE: -- 4.54 14.19

BRIEF-GW Pharma Announces Acceptance Of NDA Filing For Epidiolex (Cannabidiol)

* GW PHARMACEUTICALS ANNOUNCES ACCEPTANCE OF NDA FILING FOR EPIDIOLEX® (CANNABIDIOL) IN THE TREATMENT OF LENNOX-GASTAUT SYNDROME AND DRAVET SYNDROME Source text for Eikon: Further company coverage:

28 Dec 2017

BRIEF-GW Pharmaceuticals Reacquires Full Rights To Develop And Commercialize Sativex In U.S.

* GW PHARMACEUTICALS REACQUIRES FULL RIGHTS TO DEVELOP AND COMMERCIALIZE SATIVEX® IN U.S.

13 Dec 2017

BRIEF-GW Pharmaceuticals Announces Pricing Of Public Offering Of ADSs Raising Gross Proceeds Of $276 Million

* GW PHARMACEUTICALS PLC ANNOUNCES PRICING OF PUBLIC OFFERING OF ADSS RAISING GROSS PROCEEDS OF $276 MILLION

07 Dec 2017

BRIEF-GW Pharmaceuticals Announces Proposed Public Offering Of ADSs

* GW PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF ADSS

05 Dec 2017

Zogenix stock soars on epilepsy drug trial success

Zogenix Inc's experimental treatment for a rare form of epilepsy met the main goal in a late-stage study, the company said on Friday, more than doubling the value of its shares and hurting those of peer GW Pharmaceuticals .

29 Sep 2017

UPDATE 3-Zogenix stock soars on epilepsy drug trial success

* Analyst expects drug to become standard in Dravet treatment

29 Sep 2017

BRIEF-GW Pharmaceuticals reports Q3 results

* Gw Pharmaceuticals reports fiscal third quarter 2017 financial results and operational progress Source text for Eikon: Further company coverage:

07 Aug 2017

Earnings vs. Estimates